If CD47 is exposed (expressed) on tumor cells and elicits a "don't eat me" signal to avoid immune surveillance, then theoretically wouldn't anti-CD47 antibodies achieve the very same MOA as Bavituximab?
Unraveling this cloaking concept is part of Bavituximab's MOA, and there seems to be synergy with combo antiCD therapy. However, it also brings to light a duplicate mouse trap or redundancy, IMO..
News 
Market Data 
Discover 
